A detailed history of Parkside Financial Bank & Trust transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 1,478 shares of HALO stock, worth $70,559. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,478
Previous 1,246 18.62%
Holding current value
$70,559
Previous $65,000 29.23%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$51.3 - $64.42 $11,901 - $14,945
232 Added 18.62%
1,478 $84,000
Q2 2024

Aug 05, 2024

SELL
$37.81 - $52.4 $23,442 - $32,488
-620 Reduced 33.23%
1,246 $65,000
Q1 2024

May 01, 2024

BUY
$33.68 - $41.95 $4,479 - $5,579
133 Added 7.67%
1,866 $75,000
Q4 2023

Feb 01, 2024

BUY
$33.32 - $42.1 $57,743 - $72,959
1,733 New
1,733 $64,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.65B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.